title: ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
abstract: Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has formed the basis for a new generation of agents targeting the AR axis. Two of these agents, abiraterone acetate and enzalutamide, have been shown to prolong overall survival in patients with CRPC. Several other AR inhibitors are currently in development for the treatment of CRPC. The present article reviews ODM-201, a new-generation AR inhibitor with a unique molecular structure, in the treatment of CRPC. The design of an ongoing Phase III trial (ARAMIS) of ODM-201 in men with non-metastatic CRPC is also discussed, at a disease stage for which there is currently no approved treatment.
authors: a Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, 114 rue Edouard Vaillant, 94800 Villejuif, France.
authors: Karim
authors: K
authors: Fizazi
authors: Laurence
authors: L
authors: Albiges
authors: Yohann
authors: Y
authors: Loriot
authors: Christophe
authors: C
authors: Massard
mesh_terms: D000069501:Abiraterone Acetate / Q000494:pharmacology / Q000627:therapeutic use; D059002:Androgen Receptor Antagonists / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001549:Benzamides; D015195:Drug Design; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D015996:Survival Rate
chemical_list: D059002:Androgen Receptor Antagonists; D001549:Benzamides; D009570:Nitriles; D011720:Pyrazoles; C000607739:darolutamide; D010669:Phenylthiohydantoin; C540278:enzalutamide; D000069501:Abiraterone Acetate
keywords: ODM-201; androgen receptor inhibitors; castration resistant; efficacy; metastatic; non-metastatic; pharmacodynamics; pharmacokinetics; prostate cancer; tolerability